Claims

1. Use of a first composition comprising an immunologically effective amount of a MVA vector comprising a first polynucleotide encoding an antigenic protein or an immunogenic polypeptide thereof; and a second composition comprising an immunologically effective amount of an adenovirus vector comprising a second polynucleotide encoding the antigenic protein or an immunogenic polypeptide thereof;
   each in the manufacture of a medicament which when used in combination, is for the treatment of a filovirus, wherein the medicament based upon the first composition is to be administered to the human subject for priming the immune response, and the medicament based upon the second composition is to be administered to the human subject one or more times for boosting the immune response.

2. The use of claim 1, wherein the antigenic protein is derived from a pathogen or a tumor.

3. The use of claim 1 or claim 2, wherein the antigenic protein is derived from a filovirus.

4. The use of any one of the preceding claims, wherein the antigenic protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

5. The use of any one of the preceding claims, wherein the MVA vector comprises a polynucleotide encoding the antigenic proteins having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 5.

6. The use of any one of the preceding claims wherein the adenovirus vector comprises a polynucleotide encoding at least one antigenic protein having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

7. The use of any one of the preceding claims, wherein the adenovirus vector comprises a polynucleotide encoding the antigenic protein having the amino acid sequence of SEQ ID NO: 1.

8. The use of any one of the preceding claims, wherein the adenovirus vector is an rAd26 vector.

9. The first and second compositions according to any one of the preceding claims, for use in enhancing an immune response against an antigenic protein in a subject.

10. The first and second compositions according to any one of claims 1-8, for use in enhancing a CD4+ T cell response against an antigenic protein in a human subject.

11. The first and second compositions according to any one of claims 1-8, for use in enhancing a CD8+ T cell response against an antigenic protein in a human subject.

12. The first and second compositions of claim 10 or claim 11, wherein the enhanced CD8+ or CD4+ T cell response comprises an increase or induction of polyfunctional CD8+ or CD4+ T cells specific to the antigenic protein in the human subject.

13. The first and second compositions according to any one of claims 1-8 for use in the preparation of a pharmaceutical composition or medicament.

14. The first and second compositions of any one of claims 9-13, wherein the second composition is to be administered 1-12 weeks after the first composition.

15. The first and second compositions of any one of claims 9-13, wherein the second composition is to be administered 2-12 weeks after the first composition.